{
    "doi": "https://doi.org/10.1182/blood.V106.11.3824.3824",
    "article_title": "The Spectrum of \u03b4-Thalassemia in the Western Sicily. ",
    "article_date": "November 16, 2005",
    "session_type": "Abstracts Not Selected for Presentation",
    "abstract_text": "The detection of \u03b2-thalassemia carriers is based on the correct estimation of HbA2 values.The diagnosis of \u03b2-thalassemia carriers may be more complicated in presence of \u03b4-thalassemia because the interaction between \u03b4 and \u03b2-globin gene defects modifies the HbA 2 values. For this reason, we studied the spectrum of \u03b4-globin gene mutations present in the Sicilian population, characterized by its very high heterogeneity in \u03b2-thalassemia genotype and phenotype. The samples were selected by screening and routine prenatal diagnoses counseling for thalassemia. Among 7153 samples studied for \u03b2-thalassemia, 205 samples were selected for HbA 2 levels ranging from 0.5% to 2.0% and normal haematology parameters, suspected of being \u03b4-thal carriers in the absence of \u03b1 and \u03b2-thalassemia or hemoglobin variants, and for HbA 2 levels from 2.1% to 4.6% in subjects suspected of compound heterozygotes for \u03b4 and \u03b2-thalassemia and between 1.4% and 2.0% for \u03b4 and \u03b1-thalassemia. We have considered the value of 2% as the treshold between normal and d-carrier subjects. One-hundred-eighty-three samples showed to be positive for \u03b4-globin gene mutations.Twelve mutations were detected and among these five were new \u03b4-globin gene defects (HbA 2 -Catania, HbA 2 -Corleone, HbA 2 -Ventimiglia; HbA 2 -Montechiaro and HbA 2 -Bagheria) determining \u03b4-globin gene variants and seven were already described mutations. Among these six of them were point mutations (HbA 2 -Mitsero, HbA 2 -NYU,HbA 2 -Yialousa, HbA 2 -Coburg, HbA 2 -Fitzroy) and one a 7.2 Kb deletion mutation known as the \u03b4-Corfu\u0300 type, HBD g.5946_1262del. As it was previously shown in Sicily for \u03b2-thalassemia, only three mutations account for 91% (HbA 2 -Yialousa, HbA 2 -NYU, IVS II-3\u2032 A\u2192G) of the overall \u03b4-globin gene defects. HbA 2 -Yialousa (g.82G\u2192T) is the most common mutation found in Sicilian population (81%) while the other eleven mutations are less frequent between 0.5 to 5.5%. These findings suggest that in Sicily \u03b4-thalassemia is very common (2.5%) and as it was described, previously, for the \u03b2-thalassemia mutations,this also is very heterogeneous (twelve mutations). This information is noteworthy considering the implication that the interaction between \u03b2 and \u03b4-thalassemia could determine in terms of HbA2 decrease in subjects heterozygotes for \u03b2-thalassemia. HbA2 levels in \u03b4-thalassemia and \u03b4 globin gene variants with and without interaction with \u03b1 or \u03b2-globin gene mutations. The \u03b4-alleles are all in heterozygote state except three cases with homozygosis.   \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1 G\u03b3-158/G\u03b3 1.1 1  \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.7\u00b10.2 113  \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  2.1\u00b10.1 4  \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  0.7\u00b10.1 3  \u03b2A/\u03b2(IVS1,110) \u03b1\u03b1/\u03b1\u03b1  3.35\u00b10.15 2  \u03b2A/\u03b2(cd39) \u03b1\u03b1/\u03b1\u03b1  3.5 1 Hb A2-Yialousa \u03b2A/\u03b2(IVS1,1) \u03b1\u03b1/\u03b1\u03b1  3.5 1  \u03b2A/\u03b2(\u221287G) \u03b1\u03b1/\u03b1\u03b1  4.6 1  \u03b2A/\u03b2(\u2212101) \u03b1\u03b1/\u03b1\u03b1  2.8 1  \u03b2A/\u03b2(IVS1,6) \u03b1\u03b1/\u03b1\u03b1  3.0\u00b10.2 4  \u03b2A/\u03b2S \u03b1\u03b1/\u03b1\u03b1  2.7\u00b10.1 5  \u03b2A/\u03b2A \u03b1\u22123.7\u03b1/\u03b1\u03b1  1.8\u00b10.2 5  \u03b2A/\u03b2A \u03b1\u221220.5\u03b1/\u03b1\u03b1  1.4\u00b10.1 2  \u03b2A/\u03b2A \u03b1\u2212Med\u03b1/\u03b1\u03b1  1.6\u00b10.1 2  \u03b2A/\u03b2A \u03b1NcoI\u03b1/\u03b1\u03b1  1.7\u00b10.2 2  \u03b2A/\u03b2A \u03b1HphI\u03b1/\u03b1\u03b1  1.7\u00b10.2 2 Hb A2-NYU \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.5\u00b10.2 9  \u03b2A/\u03b2(Valletta) \u03b1\u22123.7\u03b1/\u03b1\u03b1  1.6 1 Hb A2-Mitsero \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.9\u00b10.2 3  \u03b2A/\u03b2A \u03b1\u22123.7\u03b1/\u03b1\u03b1  1.6 1 Hb A2-Coburg \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1 1 Hb A2-Fitzroy \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.4\u00b10.2 3 Hb A2-Catania \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.2 1 Hb A2-Corleone \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.6 1 Hb A2-Ventimiglia \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  2 1 Hb A2-Montechiaro \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.3 1 Hb A2-Bagheria \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.7 1 7.2 Kb deletion \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.4\u00b10.1 3  \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.5\u00b10.2 4 IVS II-3\u2032 \u03b2A/\u03b2(IVS1,110) \u03b1\u03b1/\u03b1\u03b1  3.3\u00b10.2 3  \u03b2A/\u03b2 \u03b1\u03b1/\u03b1\u03b1\u03b1  2.5 1 GENOTYPE \u03b4 GENOTYPE\u03b2 GENOTYPE\u03b1 GENOTYPE\u03b3 HbA2% N\u00b0 OF \u03b4 CARRIERS  \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1 G\u03b3-158/G\u03b3 1.1 1  \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.7\u00b10.2 113  \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  2.1\u00b10.1 4  \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  0.7\u00b10.1 3  \u03b2A/\u03b2(IVS1,110) \u03b1\u03b1/\u03b1\u03b1  3.35\u00b10.15 2  \u03b2A/\u03b2(cd39) \u03b1\u03b1/\u03b1\u03b1  3.5 1 Hb A2-Yialousa \u03b2A/\u03b2(IVS1,1) \u03b1\u03b1/\u03b1\u03b1  3.5 1  \u03b2A/\u03b2(\u221287G) \u03b1\u03b1/\u03b1\u03b1  4.6 1  \u03b2A/\u03b2(\u2212101) \u03b1\u03b1/\u03b1\u03b1  2.8 1  \u03b2A/\u03b2(IVS1,6) \u03b1\u03b1/\u03b1\u03b1  3.0\u00b10.2 4  \u03b2A/\u03b2S \u03b1\u03b1/\u03b1\u03b1  2.7\u00b10.1 5  \u03b2A/\u03b2A \u03b1\u22123.7\u03b1/\u03b1\u03b1  1.8\u00b10.2 5  \u03b2A/\u03b2A \u03b1\u221220.5\u03b1/\u03b1\u03b1  1.4\u00b10.1 2  \u03b2A/\u03b2A \u03b1\u2212Med\u03b1/\u03b1\u03b1  1.6\u00b10.1 2  \u03b2A/\u03b2A \u03b1NcoI\u03b1/\u03b1\u03b1  1.7\u00b10.2 2  \u03b2A/\u03b2A \u03b1HphI\u03b1/\u03b1\u03b1  1.7\u00b10.2 2 Hb A2-NYU \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.5\u00b10.2 9  \u03b2A/\u03b2(Valletta) \u03b1\u22123.7\u03b1/\u03b1\u03b1  1.6 1 Hb A2-Mitsero \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.9\u00b10.2 3  \u03b2A/\u03b2A \u03b1\u22123.7\u03b1/\u03b1\u03b1  1.6 1 Hb A2-Coburg \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1 1 Hb A2-Fitzroy \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.4\u00b10.2 3 Hb A2-Catania \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.2 1 Hb A2-Corleone \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.6 1 Hb A2-Ventimiglia \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  2 1 Hb A2-Montechiaro \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.3 1 Hb A2-Bagheria \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.7 1 7.2 Kb deletion \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.4\u00b10.1 3  \u03b2A/\u03b2A \u03b1\u03b1/\u03b1\u03b1  1.5\u00b10.2 4 IVS II-3\u2032 \u03b2A/\u03b2(IVS1,110) \u03b1\u03b1/\u03b1\u03b1  3.3\u00b10.2 3  \u03b2A/\u03b2 \u03b1\u03b1/\u03b1\u03b1\u03b1  2.5 1 GENOTYPE \u03b4 GENOTYPE\u03b2 GENOTYPE\u03b1 GENOTYPE\u03b3 HbA2% N\u00b0 OF \u03b4 CARRIERS View Large",
    "topics": [
        "sicily",
        "thalassemia",
        "hemoglobin a",
        "globins",
        "hemoglobin a2",
        "hemoglobin",
        "prenatal diagnosis",
        "screening",
        "thalidomide",
        "heterogeneity"
    ],
    "author_names": [
        "Aurelio Maggio, MD",
        "Cristina Passarello, PhD",
        "Gaetano Ruggeri, MD",
        "Pietro Teresi, MD",
        "Maurizio Anza\u0300, MD",
        "Anna Meo, MD",
        "Antonino Giambona, PhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Aurelio Maggio, MD",
            "author_affiliations": [
                "Divisione di Ematologia II, AO V. Cervello, Palermo, Italy"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Cristina Passarello, PhD",
            "author_affiliations": [
                "Divisione di Ematologia II, AO V. Cervello, Palermo, Italy"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gaetano Ruggeri, MD",
            "author_affiliations": [
                "Distretto Sanitario 4, ASL 6, Palermo, Italy"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pietro Teresi, MD",
            "author_affiliations": [
                "Distretto Sanitario 4, ASL 6, Palermo, Italy"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maurizio Anza\u0300, MD",
            "author_affiliations": [
                "Distretto Sanitario 4, ASL 6, Palermo, Italy"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Anna Meo, MD",
            "author_affiliations": [
                "Pediatrics, Policlinico Universitario \u201cG. Martino\u201d, Messina, Italy"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonino Giambona, PhD",
            "author_affiliations": [
                "Divisione di Ematologia II, AO V. Cervello, Palermo, Italy"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-04-27T15:38:23",
    "is_scraped": "1"
}